Newsletter · 2026-06-26 · Ashutosh Agarwal

AbbVie Leads a Pharma Merger Wave Ahead of Medicare GLP-1 Coverage - The Healthcare Pulse - Week of June 26, 2026

Weekly healthcare podcast intelligence brief for the week of June 19-26, 2026. An M&A frenzy podcasters dubbed merger mania (headlined by AbbVie's $10.9B Apogee buy) ran alongside the run-up to Medicare's GLP-1 Bridge Program, which goes live July 1, while GLP-1 commentary turned to placebo-arm contamination, a retatrutide compassionate-use mystery, and whether the bridge actually reaches patients.

The Healthcare Pulse

Week of June 26, 2026: AbbVie Leads a Pharma Merger Wave Ahead of Medicare GLP-1 Coverage

This Week at a Glance

Two stories dominated healthcare conversation this week: an M&A frenzy that podcasters openly called "merger mania," and the run-up to Medicare's GLP-1 Bridge Program, which goes live July 1. AbbVie's ~$10.9B grab of Apogee headlined a year that has already seen 33 billion-dollar pharma deals ($134B), the busiest pace since 2019, as Big Pharma scrambles to backfill a ~$300B patent cliff. Meanwhile GLP-1 commentary shifted from "how big is the market" to thornier questions: placebo-arm contamination corrupting rival obesity trials, a "compassionate use" mystery around Eli Lilly's next-gen drug, and whether a temporary Medicare program will actually reach patients. Managed care (UnitedHealth) and ASCO oncology data rounded out the week.

The People Driving the Conversation

Lou Whiteman & Matt Frankel (Motley Fool) framed the M&A wave. Whiteman on the structural driver: "There's an estimated $300 billion in annual revenue coming off patent in the next few years. That's prompting a lot of companies to either find bigger partners or, if you're big enough, find new revenue streams." On Eli Lilly: "I don't think there's a better run big pharma right now... I love that they are investing in their future, investing even beyond GLP-1s." The two then split on Pfizer (see Debates). (Motley Fool Hidden Gems Investing, June 23.)

Allison DeAngelis (STAT) captured the deal mood: "This year is exceeding the hopes and the expectations. Pharmaceutical companies and even some large biotech companies have spent around $134 billion on M&A as they kind of get ready for patent cliffs." She flagged a notable widening of the buyer pool, "companies like Insight, Biogen, UCB that are... not usually the type that are going in and making these large acquisitions." (The Readout Loud, June 25.)

Lizzie Lawrence (STAT) broke the week's oddest story: Lilly opened an FDA compassionate-use pathway for its triple-G obesity candidate retatrutide for a single 79-year-old patient, fueling speculation (denied by the White House) that it was President Trump. Lawrence: "The fact that Lilly would do this on a single patient basis is notable and raises questions about whether it was special treatment." (The Readout Loud, June 25.)

Paul Bananos (BioCentury) explained the strategic logic of AbbVie/Apogee: the lead asset (atopic-dermatitis biologic "Zumi") offers ~quarterly dosing versus every two-to-four weeks for Lilly's Ebglis and Sanofi/Regeneron's Dupixent, "there's a dosing advantage that usually leads to patient preferences, adherence advantages." (BioCentury This Week, June 23.)

Dr. Angela Fitch (Known Well), the obesity-medicine advocate, on the Medicare Bridge Program: "millions of people, maybe up to 60 million people, who were boxed out of obesity treatment before July 1st will now have access for $50 a month." She credited the most-favored-nation negotiation for getting "Lilly and Novo to the table to agree to that $250 price point." (On The Pen, June 23.)

Stacie Dusetzina (Vanderbilt) supplied the counterweight, warning of a slow, messy rollout: "I would anticipate that there will be quite a slow start... even educational materials that would prepare all of these groups for processing the prior authorizations and processing the claims, like all of this information is coming out relatively late." (NEJM Interviews, June 24.)

Jakob Emerson (Becker's) toured UnitedHealth's HQ and came away describing a company remaking itself as a tech/data vendor: "the company is presenting itself now more as a technology and data company." He relayed COO Mike Baker's striking post-crisis reflection that the firm "paused a soul search a little bit. And you ask yourself, am I missing something here? Are we really part of the problem?" (Becker's Healthcare Podcast, June 23.)

Nancy Prial (Essex Investment Management) made the cleanest fund-manager rotation call of the week, out of crowded AI, into small/mid-caps and healthcare: "we think healthcare, in fact, is one of the biggest beneficiaries of AI... We're starting to see an increase in M&A activity. And the FDA is accelerating their pace of approving new drugs." (Schwab Network, June 23.)

The Key Debates

1. Pfizer (PFE): value trap or patient-investor's dividend play?

The Motley Fool hosts staged this explicitly. Whiteman's "gentle bear": "They have Prevnar... coming off this year. Two big cancer drugs are going to follow in 2027. And they don't have a clear next big thing on the horizon... this could get worse before it gets better. I'm in no rush to jump in here." Frankel's "gentle bull": near-term expirations cost "about $17 to $18 billion in annual revenue out of more than $63 billion... These are priced into the stock... It's got a nearly 7% dividend yield... I'd be a buyer of Pfizer... but really only because I have a five-year time horizon." (Motley Fool Hidden Gems Investing, June 23.) Sell-side echoes the standoff: PFE is flagged as a potential alternate Apogee suitor [BTIG via thefly], but carries the heaviest patent-cliff overhang in large-cap pharma.

2. The Medicare GLP-1 Bridge Program: breakthrough access vs. a bridge to nowhere.

Bull case (Dr. Angela Fitch, On The Pen, June 23): up to ~60M newly eligible at $50/month, and the negotiated ~$250 price point "holds a lot more promise for us to come along and sort of codify this thing and make it a forever." Bear/skeptic case (Dusetzina, NEJM, June 24): the program runs outside Part D, sunsets end-2027 with no successor "Balance" model in place, layers a confusing multi-step prior-auth process, and strips out the behavioral/lifestyle counseling that was meant to accompany it, "not having those wraparound services" is a real downside. Even Fitch conceded: "the bridge is a temporary thing. And I think that's the concern."

3. UnitedHealth (UNH): trough-and-recovery or value trap?

On the tape, Becker's framed UNH as a bellwether reinventing itself around AI and Optum software sales while absorbing Medicare Advantage reimbursement headwinds and Medicaid volatility (Becker's, June 23). The sell-side spread is unusually wide: bulls at JPMorgan ($466) and Bernstein ($492) lean on Optum Health margin recovery and the +2.48% 2027 MA rate, while TD Cowen sits Street-low at $197 on sluggish growth and behavioral-health licensure headwinds [investing.com, fool.com]; BofA nudged its target to $475 from $450, getting "more comfortable with cost trend" into Q2 [thefly].

4. Eli Lilly vs. Novo Nordisk: priced-for-perfection leader vs. deep-value turnaround.

Q1 data crystallized Lilly's lead, Mounjaro hit $8.66B (more than doubling YoY) and dethroned Merck's Keytruda as the world's top-selling drug; with Zepbound, the tirzepatide franchise did $12.8B in the quarter, while Novo's Ozempic (-$602M QoQ) and Wegovy (-$551M) both slipped (Citeline Scrip, June 22). Bulls price Lilly to $1,251 (BofA) and a Street-high $1,500 (Citi); HSBC stays defensive at $850 on valuation/$1T-cap concerns; Berenberg ($1,135, Hold) and Leerink ($1,232, Outperform) both raised this week [thefly]. The contrarian Novo case is a deep-value turnaround post-CagriSema miss (Goldman $47 on the ADR) [yahoo.com].

5. Amgen (AMGN): obesity optionality vs. legacy overhangs.

Bulls (Morgan Stanley $340, Mizuho $303) point to the MariTide Phase 3 obesity readout and Horizon synergies; bears anchor on the 2016-18 IRS tax litigation overhang and a Harbour BioMed patent loss. Target range is a remarkably wide $200-$427 [tikr.com, simplywall.st]. Note: this debate lived in the financial press this week, not in podcasts (see gaps).

Hot Topics Under Debate

• The retatrutide "compassionate use" mystery (LLY). A single, well-connected 79-year-old got early access to Lilly's triple-G candidate via an FDA pathway normally reserved for terminal illness. Obesity experts told STAT they'd never seen a compassionate-use program for an obesity drug, and questioned the fairness, Dr. Angela Fitch noted "there's 40 million people this could apply to" and said Lilly hadn't responded to her inquiries about poor-responder patients. (The Readout Loud, June 25.)

• Placebo-arm contamination is corrupting obesity trials. With branded GLP-1s widely available, placebo patients realize they aren't losing weight (~3 months in) and start buying Wegovy/Zepbound off-protocol. In Boehringer's Phase 3 Synchronize-1, "40 participants or 16% of the placebo arm... disclosed that they had started taking GLP-1 medications," doubling expected placebo-arm weight loss to -5.4% and casting doubt on whether the data is even filable; Roche's CT388 study saw 34% placebo dropout. (Citeline Scrip, June 22.) This is a quietly important read-through for every obesity developer chasing Lilly and Novo.

• AbbVie / Apogee (ABBV/APGE), $10.9B, $135.11/share, ~49% premium. Read-throughs rippled across the sell-side: positive for immunology peers KYMR, EVMN, CNTB, CLDX, NKTR [Canaccord] and Paragon spinouts JBIO/ORKA/SYRE/CBIO [BTIG], "net negative" for Regeneron [RBC, $707 SP], with JNJ, PFE and Novartis named as possible counter-bidders [BTIG]. TD Cowen called the $10.9B valuation "reasonable" and expects a Q3 close [thefly].

• FDA reverses course on rare-disease/gene-therapy approvals. Under prior CDER-bio leadership (Vinay Prasad), programs were rejected for lacking placebo arms; the agency has since reversed at least three decisions and now accepts natural-history controls. uniQure's Huntington's gene therapy AMT-130, which showed a 75% slowing of disease progression, can now file a BLA in Q3. (BioCentury This Week, June 23.) The hosts noted this regulatory thaw is itself fueling the M&A frenzy for clinical-stage assets.

• A CAR-T first for solid tumors. China's NMPA approved CARsgen's satri-cel, described as the world's first CAR-T approved for a solid tumor, a genuine modality milestone (BioCentury This Week, June 23; Fierce Pharma, OncLive).

Emerging Themes to Watch

• Geopolitics is reshaping China licensing ("BINSA"). Pfizer's $10.5B Innovent and BMY's $15.2B Hengrui deals triggered the proposed Biotech Investment National Security Act (introduced June 2), and DoD added WuXi AppTec to its 1260H list. On the other side, Hengrui's strategy chief detailed a 100+ NME pipeline and three deal structures aimed squarely at Western partners (The BioCentury Show, June 25), the China-innovation supply remains huge even as the U.S. policy door tightens [Fierce Biotech, BioPharma Dive].

• IRA drug-pricing codification. CMS's June 12 (400+ page) proposed rule codifies the Medicare Drug Price Negotiation Program for 2029 and tightens fixed-combination rules, headline risk for JNJ, BMY, MRK and REGN, though RBC expects legal challenges to blunt the practical impact [thefly; Holland & Knight].

• GLP-1s go oral and pleiotropic. Beyond injectables: oral small-molecule aleniglipron showed up to 12.1% weight loss in Phase II [Northwestern], and emerging data tie GLP-1s to mortality and cancer-progression benefits [News Medical, CBC News]. The therapeutic story is broadening well past weight loss.

• AI in drug discovery keeps compounding. AlphaFold/Isomorphic, NVIDIA's BioNemo, and Verge Genomics' $706M Lilly ALS partnership all surfaced this week; Tempus AI raised 2026 guidance. Nancy Prial's thesis, healthcare as a top AI beneficiary on both discovery and approval-speed, is the investable framing (Schwab Network, June 23).

• Revolution Medicines and the "undruggable" RAS. At ASCO, Revolution's daraxonrasib roughly doubled median overall survival (6.6 to 13.2 months, HR ~0.4) in previously treated metastatic pancreatic cancer, and worked in both RAS-mutated and wild-type patients, with three more selective RAS molecules behind it (Oncology Overdrive, June 25). Watch as a high-conviction pipeline story heading into an FDA submission.

• Managed-care reinvention. UNH repositioning as a tech/data infrastructure vendor via Optum (selling software to hospitals, PBMs, even other payers) is a structural shift worth tracking against the MA reimbursement and Medicaid-redetermination backdrop (Becker's, June 23).

Stocks on the Radar

Note: Schwab Network's Nancy Prial also pitched a CNS specialty-pharma name (transcribed phonetically as "Axelom"), approved Alzheimer's-agitation and major-depressive-disorder drugs, ~$600M revenue run-rate, ~$12B market cap, +150% over 52 weeks, a profile consistent with Axsome Therapeutics (AXSM). Treat the ticker as unconfirmed from audio.

Upcoming Catalysts (next ~2 weeks and near-dated)

• July 1, 2026: Medicare GLP-1 Bridge Program goes live (~$50/month; runs through end-2027). LLY/NVO demand and uptake pace the key watch items.
• Q3 2026: AbbVie/Apogee (APGE) expected to close, watch for competing bids.
• Q2 earnings season (approaching): UNH cost-trend / MA repricing is the sector's focal point.
• Amgen MariTide Phase 3 obesity readout: timing unspecified in sources, but the swing catalyst for AMGN.
• FDA leadership: reports the administration may replace Commissioner Makary, a sector-wide regulatory-tone risk [PBS News Hour].
• Reference (further out): Nuvalent PDUFAs, zidesamtinib Sep 18, neladalkib Nov 27, 2026; Gilead Yeztugo oral PrEP PDUFA Feb 2, 2027; Medicaid work requirements effective Jan 1, 2027 (overhang for CNC, ELV).

The Bottom Line

This week reinforced a barbell shaping healthcare: at one end, a deal-driven scramble to outrun the patent cliff (AbbVie, Merck KGaA, GSK, Sun Pharma) that, helped by a friendlier FDA, is re-rating clinical-stage and rare-disease assets; at the other, a policy and access story (the Medicare GLP-1 Bridge, IRA price codification, BINSA) whose execution is far messier than the headlines suggest. Eli Lilly remains the consensus quality long, but the more interesting setups are the disagreements: Pfizer's dividend-vs-cliff standoff, UNH's wide bull/bear gap, and Novo's contrarian value case. For pipeline watchers, the RAS breakthrough (Revolution Medicines) and the FDA's gene-therapy reversals are the signal under this week's M&A noise. The near-term tape will trade on July 1 GLP-1 uptake and Q2 managed-care cost trends.